About the Company
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CASI News
CASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese Patients
CASI Pharmaceuticals Inc (NASDAQ:CASI) and BioInvent International AB announced preliminary efficacy data for BI-1206 in ...
CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, proudly announced ...
CASI Mar 2024 10.000 call
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent ...
CASI Pharma Posts Positive BI-1206 Interim Phase 1 Data In R/R INHL; Stock Climbs In Pre-market
Shares of CASI Pharmaceuticals, Inc. (CASI) were gaining more than 49 percent in pre-market activity on Nasdaq after the ...
CASI stock rises on positive interim data from early stage trial for its NHL treatment in China
CASI Pharmaceuticals (Nasdaq: CASI) shares rose 25% at $6.36 after company and BioInvent International AB (BINV) announced preliminary encouraging data ...
AI Might Shape What Comes Next for Apple
After Nvidia's impressive $750 billion surge this year thanks to booming demand for AI chips, investors are on the hunt for ...
Aptevo Therapeutics: Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
SEATTLE, WA / ACCESSWIRE / March 18, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprie ...
Loading the latest forecasts...